ClinicalTrials.gg
CompletedNCT05787002Updated Apr 27, 2025

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.

A Phase 1 interventional study of AZD0780 and Rosuvastatin in Dyslipidemia, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was May 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing laroprovstat in Dyslipidemias — none open to participants now, 1 under way, 1 of them phase 3. laroprovstat · Dyslipidemias.

Enrollment
9th of 11
16 · median 59
Started
2023
with 1 other
Phase 1
8 of 11
none open now
Registered
2nd of 11
by date
Lead sponsor
11 of 11
AstraZeneca

Among the 11 studies testing laroprovstat in Dyslipidemias, this one is the 9th largest by enrollment, is one of 2 that started in 2023, is one of 8 in phase 1, and was the 2nd registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 11 studies testing laroprovstat in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →

About laroprovstat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing laroprovstat in Dyslipidemias as a file.
02

Study summary

The purpose of the study is to assess the effect of AZD0780 on the pharmacokinetics of rosuvastatin, and to assess the safety and tolerability of AZD0780 single dose, in healthy participants administered alone and in combination with rosuvastatin.

Read the detailed description

Eligible participants will be randomized, in a 1:1 ratio into 2 of the treatment arms. Each participant will receive 2 treatments in total throughout the study. The following treatments will be given in randomized order in fasting state:

Treatment A: single dose of rosuvastatin tablet alone

Treatment B: single dose of rosuvastatin tablet + AZD0780 tablet

The study will comprise:

  1. A Screening Period of maximum 28 days.
  2. Two Treatment Periods up to 3 days
  3. A follow-up period of 10 to 12 days after the last administration of the study drug.

Following an overnight fast (minimum 10 hours) participants will receive either of the two treatments and will remain resident in the Clinical Unit until up to 48 hours after dosing of the study drug (up to Day 3).

The total duration of the study will be up to 9 weeks.

03

Conditions studied

  • Dyslipidemia

Keywords

  • Hypercholesterolemia
  • elevated Low-density lipoprotein-cholesterol (LDL-C) levels
  • Drug-drug interaction
  • Healthy Participants
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written prior to any study specific procedures.
  • Healthy male and female participants (of non-) aged 18 to 60 years, inclusive, with suitable veins for cannulation or repeated venipuncture.
  • Females must have a negative pregnancy test at screening and must not be lactating
  • Participants with between 18 and 30 kg/m\^2, inclusive, and weighing between 50 kg and 100 kg, inclusive

Exclusion criteria

Exclusion Criteria:

  • History or presence of gastrointestinal, hepatic or renal disease, or any other disease or disorder
  • Any positive result on screening for serum surface antigen, antibody, or .
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first vaccination within 30 days prior to randomization and second vaccination within 10 days of screening
  • Confirmed Coronavirus disease 2019 (COVID-19) infection at admission, by Polymerase chain reaction (PCR) test
  • Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening
  • History or presence of severe allergy/
  • Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months prior to screening
  • Positive screen for drugs of abuse, alcohol, or cotinine at screening
  • Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of the study drug
  • Any clinically significant abnormalities in clinical chemistry, hematology, coagulation, urinalysis results, or vital signs
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Treatment sequence A-B

    Participants will receive treatments in the following sequence, a single dose of rosuvastatin tablet alone (Treatment A) in period 1, and then a single dose of rosuvastatin tablet + Dose X AZD0780 tablet (Treatment B) in period 2.

    Drug: AZD0780 · Drug: Rosuvastatin

  • Experimental
    Treatment sequence B-A

    Participants will receive 1 treatment during each study period in the following sequence: a single dose of rosuvastatin tablet + AZD0780 tablet (Treatment B) in period 1 and then a single dose of rosuvastatin tablet alone (Treatment A) in period 2.

    Drug: AZD0780 · Drug: Rosuvastatin

Interventions

  • AZD0780 will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.

  • Rosuvastatin will be administered orally as a single dose after an overnight fast of at least 10 hours with approximately 240 mL of water.

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration-time curve from 0 to infinity (AUCinf) of Rosuvastatin

    The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose

  2. Area under the plasma concentration-curve from 0 to the last quantifiable concentration (AUClast) of Rosuvastatin

    The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose

  3. Maximum observed plasma concentration (Cmax) of Rosuvastatin

    The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose

  4. Terminal elimination half-life (t½λz) of Rosuvastatin

    The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose

  5. Time to reach maximum observed concentration (tmax) of Rosuvastatin

    The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose

  6. Apparent total body clearance (CL/F) of Rosuvastatin

    The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose

  7. Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of Rosuvastatin

    The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose

  8. Area under plasma concentration-time curve from 0 to infinity (AUCinf) of AZD0780

    The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose

  9. Area under the plasma concentration-curve from 0 to the last quantifiable concentration (AUClast) of AZD0780

    The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose

  10. Maximum observed plasma concentration (Cmax) of AZD0780

    The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose

  11. Time to reach maximum observed concentration (tmax) of AZD0780

    The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose

  12. Terminal elimination half-life (t½λz) of AZD0780

    The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose

  13. Apparent total body clearance (CL/F) of AZD0780

    The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose

  14. Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of AZD0780

    The effect of AZD0780 on the PK of rosuvastatin in healthy participants will be assessed.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 36 and 48 hours post-dose

Secondary outcomes

  1. Number of participants with Adverse Events

    The safety and tolerability of AZD0780 in combination with rosuvastatin in healthy participants will be assessed.

    Time frame: From Screening (≤ 28 days to Day -2) until Follow-up Visit (10 to 12 days post-final dose)

07

Study locations

1 site
  • Research Site
    Brooklyn, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in May 2023, 2 months.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 2 months is close to that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2023
First posted
Mar 28, 2023
StartActual
Mar 9, 2023
Primary completionActual
May 15, 2023
CompletionActual
May 15, 2023
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05787002
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 28, 2023
Start date
Mar 9, 2023
Primary completion
May 15, 2023
Completion
May 15, 2023
Last update
Apr 27, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Laroprovstat

Start the discussion